Support The Moscow Times!

Russia’s Sputnik V Coronavirus Vaccine ‘Reasonably Effective’ – British Experts

India, Brazil, China and South Korea are among the countries set to localize production of the Sputnik V vaccine. Natalia Kolesnikova / AFP

Russia’s highly touted Sputnik V vaccine is “reasonably effective” at preventing the coronavirus based on preliminary results from its mass trials but questions over its data still remain, British vaccine experts told Canada’s CBC News broadcaster Saturday.

Sputnik V’s developers announced the vaccine’s 95% efficacy last week, citing data obtained 21 days after volunteers received the second of its two doses. Much like previous Sputnik V results, the news was met with initial skepticism by Western scientists, who question the integrity of the data released under the Kremlin’s careful watch.

"I see no reason to doubt" the results published by Russia’s state-run Gamaleya research center, Ian Jones, professor of virology at the University of Reading, told the CBC. 

"I agree that their initial results caused consternation, but I don't think it's because they weren't valid. They were released a bit soon,” Jones said.

Sputnik V's results are "consistent with what we see with other [adenovirus-based] vaccines," Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, told the CBC.

This allows one to assess that the Russian vaccine is “reasonably effective," Evans said, but does not necessarily mean that the data released by Russia can be trusted. 

"We do not know how carefully their trials are monitored and how carefully they are reported. We do not know that," he said.

Italian biologist Enrico Bucci, one of the scientists who openly questioned Sputnik V's Phase 1 trial data, told the CBC that the latest results did not convince him of the vaccine’s efficacy as they contained several notable discrepancies. 

“The sample is too low to claim any percentage of efficacy,” Bucci said. 

Despite the skepticism, more than 50 countries have already requested to purchase or localize production of Sputnik V. However, Evans said he believes that these countries’ decisions were mainly based on confidence in the science behind the vaccine. 

"The countries that are buying it are buying it on trust that the Russians have produced something," Evans said. 

Sign up for our free weekly newsletter

Our weekly newsletter contains a hand-picked selection of news, features, analysis and more from The Moscow Times. You will receive it in your mailbox every Friday. Never miss the latest news from Russia. Preview
Subscribers agree to the Privacy Policy

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more